Australia's Chimeric rises as co expands license deal with University of Pennsylvania
29/06/2022 04:14
** Shares of biotech firm Chimeric Therapeutics CHM.AX
rise as much as 8.7% to A$0.1, hitting their highest since June
14
** Co says it has expanded a license agreement for its
antigen receptor therapies with the University of
Pennsylvania urn:newsml:reuters.com:*:nFWN2YF15X
** Says under deal, it will buy a non-exclusive, "know-how
license" to use the university's third-generation lentiviral
vector plasmid system for the development and commercialisation
of CHM 2101
** Says amended license to allow co to manufacture
clinical-grade lentiviral vector for use in its phase I study
for treating gastrointestinal (stomach) cancers
** CHM down 63.3% YTD, as of last close
(Reporting by Riya Sharma in Bengaluru)
((Riya.Sharma@thomsonreuters.com;))